We identified 11,480 beneficiaries in the IDEAS study sample and 3,008,067 in the eligible sample. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
SDOH are potentially modifiable factors, therefore, a deeper understanding of their effects on ADRD can inform future interventions aimed at reducing ADRD prevalence and disparities. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In 2023, US life expectancy reached 78.5 years and healthy life expectancy 64.5 years, both still below prepandemic 2019 levels, with a persistent 13-14-year gap between life expectancy and healthy life expectancy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Positron emission tomography (PET) provides an in vivo molecular marker for various diseases, including Alzheimer's disease and related dementias (ADRD). 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
As demand for shoulder arthroplasty grows, adequate cost containment is of importance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The objective of this prospective study was to evaluate the cost of Alzheimer disease (AD) in Israel. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
33/100
Limited research is available on the real-world experiences of patients with dementia with Lewy bodies (DLB). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A third of Medicare beneficiaries are enrolled in Medicare Advantage (MA); however, little is known about MA beneficiaries diagnosed with Alzheimer’s disease and related dementias (AD/ADRD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Financial incentives to detect dementia resulted in more dementia diagnoses, particularly among persons at high risk of dementia and of undetected dementia but also raises concerns about diagnostic upcoding and the potential for over‐diagnosis. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We find that even for a matched sample of TM and MA patients with the same PCP, dementiadiagnosis rates are lower in MA relative to TM. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MA-PD enrollees had significantly lower utilization of PIMs than standalone PDP enrollees: a 0.7 percentage-point [95% CI: 0.5, 0.8] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia; a 3.1 percentage-point [2.6, 3.5] lower prevalence of potentially harmful drug-disease interactions in older adults with dementia and a history of falls; and a 0.5 percentage-point [0.4, 0.6] lower prevalence of high-risk medications in older adults. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among the 1,035 patients in our dataset, 176 (17%) had a dementia diagnosis. 5 key findings →
Participants: 1,035 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Using a fit‐for‐purpose validated algorithm, the 2019 annual prevalence and incidence of ADRD in the Medicare population aged 65+ with Part D enrollment was estimated to be 18% and 5.8% respectively. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Economic assessments of health and healthcare have become an integral part of policy decisions in the last decade. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Adherence to ADRD medications was not associated with specialist availability but was related to individual and socioeconomic context factors in community‐dwelling older individuals with ADRD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In the study scenario, adding plasma p -tau217 testing to SCE reduced diagnostic costs by $342/patient, through more efficient use of amyloid PET and CSF testing. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In the colocalization of cis-eQTL and GWAS signals for Hispanics, we observed a high posterior probability (posterior prob = 0.9947) for the upstream gene variant rs755980338 on chromosome 11, which locally regulates EHD1 gene (GWAS p-value = 0.009, cis-eQTL p-value = 0.0041). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This study aimed to determine the effectiveness of regular dental scaling by evaluating the association between the frequency of dental scaling and the risk of dementia in individuals with moderate to severe periodontal disease. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 19 included studies, most used quantitative designs and secondary data. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study explored the ways in which food desert coverage was reported during the COVID-19 pandemic. 1 key finding →
Participants: 85 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The case and death rates are, for example, significantly positively associated with early cases from the beginning of the epidemic, the average age, the population density and the number of people employed in elderly care. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Predictors of an AD dementia diagnosis included age (odds ratio [OR], 1.71) and use of antipsychotics (OR, 2.50) and hypertension medication (OR, 1.25). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among Medicare beneficiaries from 2008 to 2018, AD prevalence was generally stable, while MCI increased. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There were few differences in how MA plan characteristics affected choice among older adults with and without dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Incident dementia diagnoses increased in MA relative to traditional Medicare, despite an overall downward trend in diagnosis rates. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 705 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Enhancing Care for Older Adults Through the Medicare Annual Wellness Visit
- Transcriptional regulation of APH-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia
- The effects of socioeconomic status on perceived self‐efficacy among caregivers of persons with Alzheimer's disease and related dementias
- Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration
- Assessments of the Value of New Interventions Should Include Health Equity Impact
- Factors associated with high intensity of end‐of‐life care for decedents with dementia in a Medicare Advantage plan
- The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1
- The Role of Nutrients in Reducing the Risk for Noncommunicable Diseases during Aging
- Benefits and Cost of a $35 Insulin Cost-Sharing Cap for Medicare Patients
- End-of-Life Care and Health Care Spending for Medicare Beneficiaries With Dementia in Accountable Care Organizations
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →